

Daftar Pustaka

1. Govers E; Slof E; Verkoelen H, et al. Guideline for the Management of Insulin Resistance. *IJEMD*. 2015. 1 (4). doi: <http://dx.doi.org/10.16966/2380-548X.115>
2. Alberti KG; Eckel RH, Grundy SM; et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009. 120: 1640 – 1645. PMID: 19805654. doi: [10.1161/CIRCULATIONAHA.109.192644](https://doi.org/10.1161/CIRCULATIONAHA.109.192644)
3. Ranasinghe P; Mathangasinghe Y; Jayawardena R; et al. Prevalence and Trends of Metabolic Syndrome among Adults in the Asia-Pacific Region: A Systematic Review. *BMC Public Health*. 2017. 17: 101. PMID: 28109251. PMCID: PMC5251315. doi: [10.1186/s12889-017-4041-1](https://doi.org/10.1186/s12889-017-4041-1)
4. Grundy SM; Cleeman JI; Daniels SR; et al. Diagnosis and Management of the Metabolic Syndrome. *Circulation*. 2005. 112: 2735 – 2752. PMID: 16157765. doi: [10.1161/CIRCULATIONAHA.105.169404](https://doi.org/10.1161/CIRCULATIONAHA.105.169404)
5. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. *Adv Exp Med Biol*. 2017. 960: 1 – 17. PMID: 28585193. doi: [10.1007/978-3-319-48382-5_1](https://doi.org/10.1007/978-3-319-48382-5_1)
6. Ford ES; Giles WH; Dietz WH. Prevalence of the Metabolic Syndrome among US Adults: Finding from the Third National Health and Nutrition Examination Survey. 2002. *JAMA*. 286 (3): 356 – 359. PMID: 11790215. doi : [10.1001/jama.287.3.356](https://doi.org/10.1001/jama.287.3.356)
7. Sigit FS; Tahapary DL; Trompet S; et al. The Prevalence of Metabolic Syndrome and Its association with Body Fat Distribution in middle-aged individuals from Indonesia and the Netherlands: A Cross-Sectional Analysis of Two Population-Based Studies. *Diabetol Metab Syndr*. 2020. 12: 2. PMID: 31921359. PMCID: PMC6947940. doi: [10.1186/s13098-019-0503-1](https://doi.org/10.1186/s13098-019-0503-1)
8. Kassi E; Pervanidou P; Kaltsas G; et al. Metabolic Syndrome: Definitions and Controversies. *BMC Medicine*. 2011, (9): 48. PMID: 21542944. PMCID: PMC3115896. doi: [10.1186/1741-7015-9-48](https://doi.org/10.1186/1741-7015-9-48)
9. Zhu L; Spence C; Yang WJ; et al. The IDF Definition is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011- 2016. *J Clin Med*. 2020. 9: 3871. PMID: 33260754. PMCID: PMC7759813. doi: [10.3390/jcm9123871](https://doi.org/10.3390/jcm9123871)
10. Grundy, SM. Obesity, Metabolic Syndrome, and Cardiovascular Disease. *JCEM*. 2004. 89 (6) : 2595-2600.
11. Linkner, E and Humphreys, C. Insulin Resistance and The Metabolic Syndrome. *Integrative Medicine Fourth Edition*. 2018. 320 - 333.
12. Canale, MP; Villahermosa, SM; Martino G; et al. Obesity-Related Metabolic Syndrome : Mechanisms of Sympathetic Overactivity. *Int J Endocrinol*. 2013. 2013 : 865965.
13. Govers, E; Slof, E; Verkoelen, H, et al. Guideline for the Management of Insulin Resistance. *IJEMD*. 2015. 1 (4).
14. Huang, PL. A Comprehensive Definition for Metabolic Syndrome. *Dis Model & Mech*. 2009. 2 (5-6) : 231-237.
15. Chopra, AK. Metabolic Syndrome or Insulin Resistance : Evolution, Controversies and Association with Cardiovascular Disease Risk. *Indian Journal of Clinical Cardiology*. 2020. 1 (2) : 77 - 85.
16. Mendizaabal, Y; Llorens, S; Nava, E. Hypertension in Metabolic Syndrome : Vascular Pathophysiology. *Int J Hypertens*. 2013. 2013 : 230868.

17. Rochlani, Y; Pothineni, NV; Kovelamudi, S; et al. Metabolic Syndrome : Pathophysiology, Management, and Modulation by Natural Compounds. *Ther Adv Cardiovasc Disc*. 2017. 11 (8) : 215 – 225
18. Yanai, H; Tomono, Y; Ito, K; et al. The Underlying Mechanisms for Development of Hypertension in the Metabolic Syndrome. *Nutr J*. 2008. 7 :10.
19. Park, S; Kim, C; Wu, X. Development and Validation of an Insulin Resistance Predicting Model Using a Machine-Learning Approach in a Population-Based Cohort in Korea. *Diagnostics (Basel)*. 2022. 12 (1) : 212.
20. Qu, HQ; Li, Q; Rentfro, AR; et al. The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning. *Plos one*. 2011. 6 (6) : 21041.
21. Singh, Y; Garg, MK; Tandon, N; et al. A Study of Insulin Resistance by HOMA-IR and Its Value to Identify Metabolic Syndrome in Urban Indian Adolescents. *J Clin Res Pediatr Endocrinol*. 2013. 5 (4) : 245-251.
22. Purnamasari D; Soegondo S; Oemardi M; et al. Insulin Resistance Profile Among Sibling of type 2 Diabetes Mellitus (preliminary study). *Acta Med Indones*. 2010. 42 (4) : 204 – 208. PMID: [21063041](https://pubmed.ncbi.nlm.nih.gov/21063041/).
23. Bhowmik B; Afsana F; Siddiquee T; et al. Comparison of the Prevalence of Metabolic Syndrome and Its Association with Diabetes and Cardiovascular Disease in the Rural Population of Bangladesh using the Modified National Cholesterol Education Program Exper Panel Adult Treatment Panel III and International Diabetes Federation Definitions. *J Diabetes Investig*. 2015. 6 (3) : 280 – 288. PMID: 25969712. PMCID: PMC4420559. doi: [10.1111/jdi.12268](https://doi.org/10.1111/jdi.12268)
24. Sulistiowati E and Sihombing M. NCEP-ATP III and IDF Criteria for Metabolic Syndrome Predict Type 2 Diabetes Mellitus. *Universa Medicina*. 2016. 35 (1) : 46 – 55. doi: <https://doi.org/10.18051/UnivMed.2016.v35.46-55>
25. Roberts CK; Henever AL; Barnard RJ. Metabolic syndrome and insulin resistance: Underlying Causes and Modification by Exercise Training. *Compr Physiol*. 2013. 3 (1) : 1 – 58. PMID: 23720280. PMCID: PMC4129661. doi: [10.1002/cphy.c110062](https://doi.org/10.1002/cphy.c110062)
26. Zhao X; An X; Yang C; et al. The Crucial Role and Mechanism of Insulin Resistance in Metabolic Disease. *Front. Endocrinol*. 2023. 14: 1149239. PMID: 37056675. PMCID: PMC10086443. doi: [10.3389/fendo.2023.1149239](https://doi.org/10.3389/fendo.2023.1149239)
27. Samuel VT and Shulman GI. The Pathogenesis of Insulin Resistance: Integrating Signaling Pathways and Substrate Flux. *J Clin Invest*. 2016. 126 (1): 12 – 22. PMID: 26727229. PMCID: PMC4701542. doi: [10.1172/JCI77812](https://doi.org/10.1172/JCI77812)
28. Tsatsoulis A and Paschou SA. Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies and Consequences. *Curr Obes Rep*. 2020. 9 (2): 109 – 120. PMID: 32301039. doi: [10.1007/s13679-020-00375-0](https://doi.org/10.1007/s13679-020-00375-0)
29. Jaramillo PL; Arbelaez DG; Lopez JL; et al. The role of Leptin/Adiponectin ratio in Metabolic Syndrome and Diabetes. *Horm Mol Biol Clin Invest*. 2014. 18 (1): 37 – 45. PMID: 25389999. doi: [10.1515/hmbci-2013-0053](https://doi.org/10.1515/hmbci-2013-0053)
30. Yadav A; Kataria MA; Saini V; et al. Role of Leptin and Adiponectin in Insulin Resistance. *Clin Chim Acta*. 2013. 417: 80 – 84. PMID: 23266767. doi: [10.1016/j.cca.2012.12.007](https://doi.org/10.1016/j.cca.2012.12.007)
31. Shen W; Punyanitya M; Silva AM; et al. Sexual Dimorphism of Adipose Tissue Distribution across the Lifespan: a Cross-Sectional Whole-Body Magnetic Resonance Imaging Study. *Nutr Metab (Lond)*. 2009. 6:17. PMID: 19371437. PMCID: PMC2678136. doi: [10.1186/1743-7075-6-17](https://doi.org/10.1186/1743-7075-6-17)
32. Marcus Y; Segev E; Shefer G; et al. Metabolically Healthy Obesity Is a Misnomer: Components of the Metabolic Syndrome Linearly Increase with BMI as a Function of Age and Gender. *Biologu (Basel)*. 2023. 12 (5): 719. PMID: 37237531. PMCID: PMC10215588. doi: [10.3390/biology12050719](https://doi.org/10.3390/biology12050719)

33. Sonoli SS; Kothiwale VA; Channashetti RD. Alterations in Metabolic Status of Healthy Individuals With and Without Obesity During Transition from Adolescence to Young Adulthood. *Explor Med.* 2023. 4: 3-15. doi: <https://doi.org/10.37349/emed.2023.00120>
34. Saeed AA. Prevalence of Metabolic Syndrome and Its Components among Saudi Young Adults 18 – 30 Years of Age. *OJEMD.* 2019. 9: 49 – 59. doi: [10.4236/ojemd.2019.94005](https://doi.org/10.4236/ojemd.2019.94005)